| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
105,890,000 |
| Market
Cap: |
861.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.87 - $18.44 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 20.4 |
| Insider 3/6 Months : 21 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,403,436 |
1,403,436 |
16,641,531 |
| Total Buy Value |
$0 |
$15,402,661 |
$15,402,661 |
$335,402,656 |
| Total People Bought |
0 |
3 |
3 |
3 |
| Total Buy Transactions |
0 |
3 |
3 |
4 |
| Total Shares Sold |
0 |
3,594 |
5,152 |
213,978 |
| Total Sell Value |
$0 |
$53,910 |
$77,303 |
$4,167,948 |
| Total People Sold |
0 |
1 |
2 |
4 |
| Total Sell Transactions |
0 |
1 |
3 |
16 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ribas Antoni |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
43,650 |
|
- |
|
| Lacey David L. |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
70,952 |
|
- |
|
| Lambert Nicole |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
37,300 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
68,600 |
|
- |
|
| Machado Clarence Patrick |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
38,600 |
|
- |
|
| Kaneko Yasunori |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
33,300 |
|
- |
|
| Perlman Andrew J |
Director |
– • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
42,625 |
|
- |
|
| Kaneko Yasunori |
Director |
– • – |
2025-02-27 |
4 |
B |
$10.06 |
$201,200 |
D/D |
20,000 |
28,400 |
2.39 |
-20% |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2025-02-27 |
4 |
B |
$10.18 |
$201,465 |
D/D |
19,800 |
2,554,160 |
2.81 |
-20% |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2025-02-18 |
4 |
B |
$11.00 |
$14,999,996 |
D/D |
1,363,636 |
31,424,760 |
2.45 |
-27% |
|
| Markus Richard |
Chief Medical Officer |
• – – |
2025-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
75,193 |
75,193 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
213,369 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
137,623 |
|
- |
|
| Rosen Terry J |
Chief Executive Officer |
• • – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
165,000 |
2,534,360 |
|
- |
|
| Jaen Juan C. |
President |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
367,220 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
97,138 |
|
- |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2025-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
17,100 |
30,194 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2024-12-31 |
4 |
AS |
$15.00 |
$53,910 |
D/D |
(3,594) |
60,138 |
|
-42% |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2024-12-19 |
4 |
D |
$15.17 |
$45,616 |
D/D |
(3,007) |
13,094 |
|
- |
|
| Jaen Juan C. |
President |
• – – |
2024-12-15 |
4 |
D |
$16.08 |
$277,959 |
D/D |
(17,286) |
317,220 |
|
- |
|
| Jarrett Jennifer |
Chief Operating Officer |
• – – |
2024-12-15 |
4 |
D |
$16.08 |
$442,216 |
D/D |
(27,501) |
163,369 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2024-12-15 |
4 |
D |
$16.08 |
$162,392 |
D/D |
(10,099) |
63,732 |
|
- |
|
| Azoy Alexander |
Chief Accounting Officer |
• – – |
2024-12-15 |
4 |
D |
$16.08 |
$47,742 |
D/D |
(2,969) |
16,101 |
|
- |
|
| Tang Carolyn C. |
General Counsel |
• – – |
2024-12-15 |
4 |
D |
$16.08 |
$182,331 |
D/D |
(11,339) |
100,623 |
|
- |
|
| Nuyten Dimitry Sa |
Chief Medical Officer |
• – – |
2024-12-15 |
4 |
D |
$16.08 |
$126,324 |
D/D |
(7,856) |
87,518 |
|
- |
|
248 Records found
|
|
Page 1 of 10 |
|
|
0.19 (2.39%) 
